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 1 
RIASSUNTO 
La tecnologia del DNA ricombinante è un’applicazione biotecnologica la cui 
importanza è di rilevanza enorme. Nel corso del presente progetto di dottorato le 
potenzialità dei sistemi di espressione eterologa sono state utilizzate per affrontare 
due diverse problematiche: 
I. l’espressione ricombinante delle proteina PED e del dominio D4 di 
PLD1, al fine di comprendere i meccanismi alla base della loro interazione e di 
ricercare eventuali peptidi antagonisti 
II.  la generazione di linee cellulari umane stabilmente esprimenti il gene 
POTE2γ e il silenziamento di altre normalmente esprimenti tale gene, al fine di 
valutare eventuali variazioni fenotipiche nella linea cellulare ospite. 
PED (Phosphoprotein Enriched in Diabetes) è una proteina citosolica  di 15 
kDa con differenti funzioni: è stato infatti dimostrato il suo coinvolgimento in processi 
proapoptotici e la sua implicazione nei processi che determinano insulino-resistenza 
nel diabete. Il gene ped è, infatti, sovraespresso nei tessuti target dell’azione 
insulinica (tessuto muscolare scheletrico e tessuto adiposo) dei diabetici di tipo 2. La 
sua sovraespressione, in cellule in coltura e in topi transgenici, induce insulino-
resistenza, ma il meccanismo attraverso cui ciò avviene non è ancora ben chiaro. 
Attraverso diversi approcci, tuttavia, è stato verificato che PED interagisce con 
alcune fosfolipasi (PLD1 e PLD2) e diverse evidenze indicano l’interazione specifica 
con PLD1 come responsabile dell’insulino-resistenza.  Il legame di PED con PLD1 
non influisce sull’attività della proteina ma ne aumenta la stabilità; è stato inoltre 
dimostrato che l’interazione con PED è mediata dal dominio C-terminale di PLD1 
(denominato D4), comprendente i residui 712-1070. E’ stato infine dimostrato che 
bloccando l’espressione di PED (ad esempio con oligonucleotidi antisenso) la 
resistenza all’azione insulinica  e’ invertita e i livelli glicemici sono riportati a livelli 
basali. E’ dunque evidente come la ricerca di eventuali molecole in grado di bloccare 
l’interazione PED-PLD1 rappresenti un obiettivo farmacologico di enorme interesse. 
I geni POTE sono invece stati individuati attraverso tecniche bioinformatiche. 
In particolare, l’analisi di database di EST per geni specifici della prostata ha portato 
alla individuazione di una nuova famiglia di geni, denominata POTE, espressa in 
prostata, ovaie, testicoli e placenta ma non in tessuti normali. Sebbene la sua 
funzione non sia ancora nota, la presenza di dieci varainti con una identità di 
sequenza del 90-98% indica una alta pressione selettiva tesa al mantenimento di tale 
gene. Analisi mediante RT-PCR ha mostrato l’assenza di espressione di POTE in 
tessuti normali del seno e in normali linee cellulari epiteliali del seno, mentre esso 
risulta essere espresso nella maggioranza delle linee cellulari di cancro al seno, in 
particolare la variante 2γ. Inoltre, normali linee cellulari epiteliali del seno trasformate 
dagli oncogeni ErbB-2 e Ras  esprimono POTE2γ. Tutto cio’ sembra indicare il 
coinvolgimento di POTE2γ nei processi di tumorigenesi del cancro al seno. Al fine di 
una caratterizzazione preliminare di tale gene, si e’ scelto sia di generare linee 
cellulari ricombinanti per POTE2γ, sia di silenziare tale espressione in linee cellulari 
normalmente esprimenti POTE2γ, al fine di valutare eventuali variazioni fenotipiche 
e, successivamente, anche genotipiche, avvenute in seguito all’espressione o al 
silenziamento di tale gene. 
 
PED-D4: 
Il punto di partenza è stato la messa a punto dell’espressione e purificazione 
della proteina PED e del dominio D4  di PLD1.  
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Le caratteristiche della proteina PED  sono tali da avere fatto ricadere la scelta 
del sistema ospite per l’espressione sul batterio E. coli: PED e’ infatti solubile e di 
piccole dimensioni. L’amplificazione mediante PCR del c-DNA codificante per PED 
(messo a disposizione dal Prof. F. Beguinot, Dipartimento di Biologia e Patologia 
Cellulare e Molecolare, Università degli studi di Napoli Federico II) e’ stato il punto di 
partenza per il  clonaggio nel vettore di espressione petM30, tramite cui PED è 
espressa fusa alla proteina Gst e ad un tag di poli-istidine; il ceppo ospite di E. coli 
migliore è risultato essere Bl21(DE3)Star (mutante nel gene della RnasiE; ciò riduce 
la degradazione di mRNA) e la concentrazione ottimale di induttore (IPTG) pari a 1 
mM. La resa ottenuta con queste condizioni di espressione è piuttosto elevata (circa 
300 mg di proteina di fusione / l di coltura batterica) già a 37°C. L’intera proteina di 
fusione e’ stata purificata mediante FPLC su colonne His-trap (affini per l’His-tag). 
Per la purificazione della sola proteina PED, la proteina di fusione e’ stata idrolizzata 
in presenza della proteasi di TEV, essendo presente tra PED ed i suoi partner di 
fusione un linker contenente la sequenza amminoacidica specificamente riconosciuta 
da tale enzima. Infine, la miscela risultante dall’idrolisi è stata purificata su His-trap: 
essendo anche la TEV dotata di un tag di poli-istidine, PED è la sola ad essere 
recuperata nel flow-through. Il livello di purezza così ottenuto e’ ≥ 95%; per 
applicazioni in cui e’ stata necessaria una purezza ≥ 99% è stato necessario 
compiere un’ulteriore purificazione prima su colonna Gst-trap (affine per la Gst) e 
quindi su colonna a scambio anionico MonoQ HR 5/5. 
 
 
 
 
L’analisi mediante spettrometria di massa della proteina intera e digerita con 
tripsina ha confermato la sua identità. La caratterizzazione mediante spettroscopia 
CD ha invece confermato la sua corretta struttura: PED ha, infatti, all’N-terminale un 
dominio death effector (DED), caratterizzato dalla tipica struttura a 6 alfa-eliche, 
seguito da una estremità C-terminale dalla struttura irregolare. Lo spettro di 
dicroismo circolare registrato con la proteina pura al 99% ha evidenziato una 
struttura di questo tipo: 
 
 
 
 
 
kDa 
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25 
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1: Protein Pefect Marker; 
2: Proteina di fusione idrolizzata in  presenza di TEV proteasi (input His-
trap); 
3: Eluizione dopo Gst-trap ; 
4: Eluizione dopo MonoQ HR 5/5 
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La denaturazione termica di PED, seguita mediante CD, ha mostrato un alto 
valore della temperatura di melting di essa (>55°C), indice di elevata stabilità della 
proteina; essa, inoltre, si rinatura facilmente anche dopo trattamento termico.  
Anche per D4 sono stati provati diversi vettori di espressione e diversi ceppi 
batterici: le condizioni ottimali si sono avute col vettore pETM20 (in cui D4 è 
espressa fusa alla proteina TrxA e al tag di poli-istidine) in BL21(DE3)pLysS (in cui la 
presenza del plasmide pLysS permette un controllo più rigoroso dell’induzione 
dell’espressione con IPTG) in presenza di IPTG 0,1 mM, a 22°C per 16 h. Le rese di 
espressione, tuttavia, risultano essere abbastanza basse (circa 1 mg/l di coltura). La 
proteina di fusione (D4-Trx-His6) è stata quindi purificata su His-trap e poi su colonna 
a scambio anionico MonoQ HR 5/5; a causa dell’alto numero di cisteine presenti in 
D4 (5) è necessario effettuare tutte le purificazione in presenza di TCEP 1mM. Anche 
in queste condizioni, comunque, D4-Trx-His6 è piuttosto instabile nel tempo.  Inoltre, 
ogni tentativo di idrolisi in presenza della proteasi di TEV è fallito; perciò, per le 
analisi successive e’ stata utilizzata l’intera proteina di fusione D4+Trx+His6. 
Inaspettatamente, la proteina di fusione dopo MonoQ HR 5/5 risulta essere 
presente in due picchi distinti: 
 
 
 
 
 
L’analisi mediante LC-MS  ha confermato che entrambe le frazioni contengono 
la stessa proteina, che risulta essere D4+Trx+His6. Analizzando entrambe mediante 
gel filtration (Superdex200 HR 10/30) e su gel nativo, è risultato che nel primo picco 
è stata separata una forma monomerica (D4M), nel secondo una forma dimerica 
(D4D): 
 
 
La gel filtration, ripetuta con concentrazioni differenti di NaCl nel tampone di 
corsa, ha mostrato che all’aumentare della concentrazione salina l’equilibrio risulta 
spostato verso la forma monomerica, facendo ipotizzare una interazione di tipo 
ionico tra le due subunità. 
Esperimenti preliminari ELISA hanno confermato l’interazione di D4+Trx+His6 
con PED; essa è poi stata ulteriormente validata attraverso la tecnica dell’SPR, 
D4-Trx-His6 
1: MW Marker 
2: Purified da  His-trap 
3: Frazione 15 
4: Frazione 16 
5: Frazione 17 
6: Frazione 18 
7: Frazione 19 
1  2       3   4   5  6  7 
56kDa 
 D4-Trx-His6 
D4M 
Monomer 
Dimer 
Dimer 
Monomer 
D4D 
   PEAK 1 
PEAK 2 
   PEAK 1    PEAK 2 
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utilizzando un sistema Biacore 3000. PED è stato efficientemente immobilizzato sulla 
superficie di un sensore CM5, quindi concentrazioni crescenti di D4M e D4D sono 
state iniettate su esso (dopo aver verificato che Trx+His6 non lega PED): 
inaspettatamente, il dimero è incapace di legare PED, mentre  D4 monomerica lega 
PED (kD= 2±1*10-7) 
 
 
 
 
 
 
 
 
 
 
 
Il  saggio di legame così ottimizzato è stato utilizzato per la ricerca di peptidi 
inibitori dell’interazione PED-D4. A tale scopo, PED è stata idrolizzata in presenza di 
tripsina. La miscela di peptidi ottenuta è stata separata in differenti pool, in seguito 
caratterizzati mediante LC-MS; tra essi, due pool hanno dato competizione al legame 
di D4 con PED, uno contenente i peptidi 36-54, 36-57, 55-71, 58-71 e 72-83, ma 
maggiormente l’altro contenente il solo peptide 1-24, corrispondente alle prime due 
α-eliche del dominio DED. 
 
POTE2γ: 
Per la generazione delle linee cellulari esprimenti tali geni e’ stato utilizzato il 
sistema di espressione del lentivirus, in cui lentivirus derivati da HIV-1 ma incapaci di 
replicarsi sono utilizzati per introdurre ed esprimere il gene di interesse in cellule di 
mammiferi. Una volta che il lentivirus ricombinante penetra nella cellula target, l’RNA 
virale e’ retrotrascritto, importato attivamente nel nucleo e stabilmente integrato nel 
genoma dell’ospite. La selezione della linea cellulare ricombinante è infine fatta la 
resistenza alla Blasticidina delle cellule, resistenza introdotta attraverso il lentivirus 
insieme al gene d’interesse. 
Per esprimere il gene di interesse è stato usato il ViraPower Lentiviral 
Expression System (Invitrogen) per generare gli stock di virioni ricombinanti. 
L’amplificazione mediante PCR del gene POTE 2γ ed il successivo clonaggio nel 
vettore pLenti6/V5-D-TOPO (Invitrogen) ha permesso la generazione  del costrutto di 
espressione contenente i segnali (promotore, enhancer, gene codificante per la 
resistenza alla Blasticidina, ecc.) necessari per l’espressione nella linea cellulare di 
interesse. Per la preparazione dello stock virale, i costrutti ottenuti sono stati co-
transfettati (attraverso il metodo della precipitazione in BES-Calcio Fosfato) in cellule 
293T (ottimali per la generazione di stock virali) insieme ad un mix di tre plasmidi che 
forniscono in trans le proteine strutturali e replicative necessarie per la produzione 
del lentivirus. 48 ore dopo la transfezione, il sopranantante contenente i virus e’ stato 
raccolto, ultracentrifugato, risospeso in PBS e conservato a -80°C. Gli stock sono 
stati quindi titolati, ed il titolo risultante è stato 9*106 TU/ml. 
I virioni cosi’ preparati sono stati quindi utilizzati per le infezioni della linea 
cellulare MCF10A (cellule epiteliali di seno non cancerose), che non esprime né 
POTE2γ. L’RNA totale, estratto dalle cellule ricombinanti (selezionate grazie 
all’acquisita resistenza alla Blasticidina), è stato retro-trascritto in vitro in cDNA e 
  D4M 550nM 
  D4M 1.1 µΜ 
  D4M 1.7 µΜ 
  D4M 2.2 µΜ 
  D4D 1.8 µΜ 
  D4D 3.6 µΜ 
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utilizzato come stampo per una reazione di PCR con oligo specifici per POTE2γ 
(T444-T445, banda attesa di 386 bp). Lo stesso procedimento è stato effettuato con 
le cellule wild-type:  
 
 
 
 
 
 
 
 
L’analisi tramite RT-PCR, dunque, ha confermato che nelle cellule ottenute in 
seguito alla selezione è stato integrato il gene codificante per POTE 2γ. 
Il sistema del lentivirus è stato utilizzato anche come mezzo per silenziare 
POTE2γ in una linea cellulare di cancro al seno, MCF7, che normalmente esprime 
tale gene.  Per il silenziamento si e’ scelto di utilizzare il metodo dell’RNA 
interference (RNAi), fenomeno che permette una potente e specifica inibizione 
dell’espressione genica in eucarioti attraverso la degradazione di mRNA. 
L’espressione di short-hairpin RNA (shRNA, classe di RNA artificiali caratterizzati 
dall’avere una breve sequenza nucleotidica di 19-29 nucleotidi derivata dal gene da 
silenziare,  seguita da un loop di 4-15 nucleotidi e quindi da una sequenza inversa e 
complementare della sequenza target iniziale) nella linea cellulare di interesse 
determina una degradazione dell’mRNA del gene target, causando in questo modo il 
silenziamento genico.  
Prima di tutto, è stato ottimizzato il protocollo di silenziamento, utilizzando 
come target il gene lamin. Cellule MCF7 sono state infettate con lentivirus in grado di 
esprimere shRNA specifici per lamin; il silenziamento è stato poi verificato mediante 
analisi Western Blot. 
 
 
 
 
 
 
 
Avendo quindi verificato l’effettivo funzionamento del metodo scelto, sono stati 
generati gli stock di lentivirus da utilizzarsi in futuro per il silenziamento del gene  
POTE 2γ nelle cellule MCF7. 
 
Gli esperimenti eseguiti nel corso del presente progetto di dottorato hanno 
dunque permesso di ottenere informazioni sull’interazione tra PED e D4. L’assenza 
di legame con D4 in forma dimerica potrebbe avere anche importanti implicazioni 
biologiche, poichè l’aumentata attività di PLD1 riscontrata nelle cellule 
sovraesprimenti PED potrebbe essere l’effetto della distorsione degli equilibri di 
oligomerizzazione di PLD1.  E’ stata inoltre identificata una regione di PED di 
potenziale interazione con PLD1, corrispondente alle prime due α−eliche. 
Le linee cellulari ricombinanti e gli stock virali esprimenti shRNA per POTE 2γ  
saranno utilizzati per una caratterizzazione sia del genotipo che delle proteine 
espresse, al fine di rilevare eventuali variazioni. 
 
1. Marker 
2. dH2O, T444-T445 primer 
3. cDNA da MCF10A wild-type, T444-T445 primer 
4. cDNA da MCF10A/ POTE 2γ T444-T445 primer 
5. dH2O, Actin primer 
6. cDNA da MCF10A wild-type, Actin primer 
7. cDNA da MCF10A/ POTE 2γ Actin primer 
 
1 MCF7 lysate, 10 µg 
2 MCF7 lysate, 35 µg 
3 MCF7-shLamin lysate, 10 µg 
4 MCF7-shLamin lysate, 35 µg 
 
   1   2        3   4  
 
1   2    3   4   5   6    7 
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 SUMMARY 
 
In the research project described in this thesis, all the potentialities of 
recombinant DNA technology have been employed to investigate two different 
systems, PED-PLD1 and POTE. 
PED (Phosphoprotein Enriched in Diabetes) is overexpressed in skeletal 
muscle, adipose tissue and fibroblasts from type 2 diabetic individuals, this disease 
being one of the most common disorders in the world. Several lines of evidences 
suggest that ped overexpression may cause impairment of insulin-stimulated glucose 
transport through its interaction with PLD1 (Phospholipase D1). The mechanism by 
which this occurs is still unknown, but it is clear that PED lengthens PLD persistence 
in the cell rather then increasing its enzymatic activity. 
In the present study, both PED and the D4 domain of PLD1, which is the 
shortest region still able to bind to PED, were expressed and purified. 
 Hydrolysis in the presence of TEV protease enabled the cleavage of PED from 
its fusion partners and its characterization. LC-MS of the entire PED protein and 
peptide mass fingerprinting confirmed its identity. PED α-helical structure resulted 
very stable, as seen by CD analysis and thermal denaturation. 
Reducing conditions were used in all D4 manipulations, to avoid the formation 
of aggregates. Two different isoforms of D4, monomeric (D4M) and dimeric (D4D), 
were isolated. The nature of the intermolecular interaction in the dimeric form was 
checked using gel filtration chromatography at different saline concentrations. 
Preliminary ELISA assays confirmed D4-PED interaction. Real-time BIA 
technology showed that PED only interacts with the monomeric form of D4; 
moreover, using trypsin-derived peptides in a competition assay, peptide 1-24 of 
PED resulted to be a strong competitor for D4 binding, while a mixture of peptides 
36-54, 36-57, 55-71, 58-71 and 72-83 competed less efficiently. 
All these findings could also have relevant biological implications, as the 
increased PLD1 activity promoted by PED binding in vivo could be the result of a 
shifted equilibrium of PLD isoforms. 
Instead, using bioinformatics tools, the POTE gene family was identified; it 
consists of 11 highly homologous genes expressed in several different cancer types. 
In particular, POTE2γ has aroused interest as a specific target in breast cancer 
therapies. Elucidation of POTE expression patterns, regulation and its role in cancer 
cells is essential to explore its therapeutic potential.   
The lentivirus system was used to generate a stable POTE2γ expressing 
breast cell line. This system can also be employed to express sh-RNA for gene 
silencing. An experimental procedure was optimized to silence the lamin A/C gene 
and recombinant lentiviruses capable of silencing POTE expression were generated. 
Further experiments are ongoing to produce anti-POTE antibodies. 
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1. INTRODUCTION 
 
1.1 RECOMBINANT PROTEIN EXPRESSION 
One of the most powerful applications of biotechnology is the methodology of 
recombinant DNA: thanks this technology, it has been possible to develop expression 
systems capable of rapidly producing large quantities of proteins. This is of enormous 
benefit, for example, in case of proteins that can only be obtained in scarce amounts 
from natural compounds and/or that can’t be easily purified. 
Recombinant DNA technology allows the cloning of the gene of interest in an 
expression vector, an autonomously replicating plasmid containing all the signals 
necessary for the expression of the protein in a suitable host organism. The most 
common hosts are bacteria, since they duplicate rapidly and require easy and 
economic culture conditions; this allows their use to express large amounts of protein 
without high costs and difficulties. The most used microorganism is Escherichia coli: 
its genetics and physiology are well known and moreover it can be grown and 
manipulated using simple laboratory instruments. A big limit of this system, however, 
is the lack of enzyme systems to carry out specific post-translational modifications 
that many proteins need for biological activities. When such modifications are 
required, it is necessary to use expression systems based on eukaryotic cells (such 
as yeast, insect or mammalian cells). Another limit of E. coli is the expression of 
proteins as insoluble aggregates, known as inclusion bodies. In such cases, 
production of soluble protein can be improved by lowering the growth temperature or 
else recovered by renaturation from inclusion bodies; often, however, changing 
expression system is also the only solution. 
Recombinant DNA technology has also allowed expression of the target 
protein fused to peptides or proteins that promote its solubilization and/or facilitates 
any subsequent purification. The fusion partner can then be removed if it is linked to 
the gene of interest by an amminoacidic sequence containing a specific protease 
recognition site (such as TEV protease, Thrombin, Enterokinase, etc.)1. 
Each single protein, however, is characterized by a peculiar set of properties 
that do not allow a standardization of expression and purification conditions that must 
be investigated and optimized in each case. 
In the research project described in this paper, all the potentialities of 
recombinant expression have been employed as the starting point to investigate two 
different systems, PED-PLD1 and POTE. 
  
1.2 PED-PLD1 
PED (Phosphoprotein Enriched in Diabetes, Fig.1) is an ubiquitously 
expressed protein that controls cell proliferation and death and plays an important 
role in tumour development2, 3 , 4.  
 
 
 
 
 
 
 
 
 
  1MAEYGTLLQDLTNNITLEDLEQLKSACKEDIPSEKSEEITTGSAWFSFLE50 
 51SHNKLDKDNLSYIEHIFEISRRPDLLTMVVDYRTRVLKISEEDELDTKLT100 
 101RIPSAKKYKDIIRQPSEEEIIKLAPPPKKA130 
Figure 1: PED sequence 
PED ORF is four codons different from PEA-15 (Phosphprotein Enirched 
in Astrocytes): Ala→Val2, Leu→Phe8, Tyr→Ile62, Ala→Gly1245. 
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The three-dimensional structure of PED (Fig.2) consists of an N-terminal 
Death Effector Domain (DED) comprised of six antiparallel amphipatic α-helices 
closely packed around a central hydrophobic core, followed by a long and irregular 
C-terminal tail. The α-helices in the DED are connected by short loops and are 
arranged in a Greek Key topology, with α1 and α2 being centrally located. This fold 
represents the core structure typical of the death motif superfamily6 
The DED domain is followed by a Protein Kinase C (PKC) phosphorylation 
domain (residues 99-107) and a calcium/calmodulin-dependent kinase II site 
(residues 110-122)7. PED antiapoptotic function is regulated by phosphorylation of 
Ser116 and Ser1048. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has been found that PED is overexpressed in skeletal muscle, adipose 
tissue and fibroblasts from type 2 diabetic individuals by two to threefold. PED 
overexpression in normal muscle and adipose cells to levels comparable to those 
occurring in type 2 diabetes inhibits insulin-stimulated glucose transport and cell-
surface recruitment of Glut4, the major insulin-sensitive glucose transporter9. 
Moreover, transgenic mice for PED treated with a fat diet develop diabetes. Blocking 
PED expression with appropriate antisense oligonucleotides in cultured cells inverts 
insulin resistance and brings glucose to basal levels10. 
All this evidence suggests that ped overexpression may cause type 2 diabetes 
mellitus, one of the most common disorders in the world, for which it is not known 
wether if a single genetic defect is responsible for it or which mechanism causes 
impaired insulin action and secretion 11, 12. 
Mutation experiments show that PED phosphorylation, which is responsible for 
PED antiapototic function, is not involved in these changes in glucose uptake 
regulatory functions13, so a different mechanism has to be implicated. 
PED is a phospholipase D1 (PLD1) interactor which increases PLD activity. 
The mechanism on which this occurs is still unknown, but it is clear that PED 
lengthens PLD persistence in the cell rather then increasing its enzymatic activity10,14. 
PLD1 is a protein widely distributed in animals, plants, fungi and bacteria and 
is implicated in several cellular processes that include receptor signalling, control of 
intracellular membrane transport and glucose transport. 
Figure 2: PED structure 
Residues 2-14, 17-27, 33-37, 42-51, 61-69 and 73-89 comprise helices 
α1, α2, α3, α4, α5  and  α6, respectively. 
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The association of PLD N- and C-terminal halves constitutes its catalytic core. 
Individually expressed N- and C-terminal fragments of PLD1 are catalytically inactive, 
but, when coexpressed, PLD activity is reconstituted and direct interaction between 
the fragments can be observed. Interaction is observed only when N- and C-termini 
are coexpressed but not when they are individually expressed and mixed in vitro; 
thus, this self-association likely occurs during translation and may involve specific 
folding processes15, 16, 17. Requirement of intramolecular dimerization to form a 
catalytically active enzyme introduces the possibility that intermolecular interaction 
may also occur. Colocalization in COS-7 cells and coimmonuprecipitation of equal 
amounts of differentially tagged rPLD1s implies that there is an actual dimerization 
between rPLD1 molecules18.  
PLDs catalyse the hydrolysis of the phosphodiester bond of 
glycerophospholipids to generate phosphatidic acid. They are implicated in a wide 
range of cellular processes, most of which involve the phosphatidic acid product as 
an intracellular messenger15. Phosphatidic acid can also be converted to two other 
mediators, diacylglycerol (DAG) and lysophosphatidic acid19. DAG is a major PKC-α 
activator, the most common isoform of PKCs, a family of proteins that play an 
important role in signalling insulin activation on glucose transport20.  
PED induced resistance to insulin action is accompanied by an increase in 
DAG levels10 and activation of PKC-α13, both in vitro and in vivo. This evidence 
suggests that, in PED overexpressing cells, PED interaction with PLD increases its 
activity, causing a PKC-α activation through an increase of DAG levels. PKC-α 
activation then downregulates insulin induction of PKC-ζ function, impairing insulin-
stimulated glucose transport and Glut4 translocation (Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using a two-hybrid screen, the shortest PED-interacting region of PLD1 has 
been identified and named D414 (Fig.4).  
 
 
Figure 3: Effect of increased PED-PLD1interaction 
PED-PLD1 
 
DAG 
PKC-α 
PKC-ζ  
GLUCOSE 
GLUCOSE 
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Random mutagenesis subsequently revealed several D4 mutants unable to 
bind PED23 (see Table 1). 
 
MUTANTS NOT INTERACTING WITH PED MUTANTS STILL INTERACTING WITH PED 
I770M H775R 
H775L/E1054G V819G 
I777N I870T 
I805T N905Y/K981N 
V817E/S979R T906S/Q1046H 
N867K/D980V N913/D1008N 
W869R G921E/K1039E 
D903V/R1032P Q975R/D999V 
D904N D999V 
D904G/A912T N1007K 
A912G/L964R V1010A 
K922M/S939L V1045A 
S925R/V1001N  
M941T  
A948V/V1045M  
E958P  
D976V  
D1008Y  
 
 
 
The mutations are spread through out D4 and are not localized to any 
particular PED binding site; all attempts to identify this site have been 
unsuccessfull14, 24. 
Because multiple overlapping PED clones were identified in the two-hybrid 
screen, PED region 53-112 was assumed to be the PLD1 interacting site. 
Phosphorylation of Ser104 doesn’t affect PED-PLD1 interaction. 
 
1.3 REAL-TIME BIA 
Real-time BIA (Biomolecular Interaction Analysis) is a technology that allows 
the monitoring of biomolecular interactions in real time without labelling any of the 
 712RSLSYPFLLPKSQATAHELRYQVPGAVPAKVQLLRSAADWSAGIKHHEES761 
 762IHAAYIHVIENSKHYIYIENQFFISCADDKVVFNKVGDRIAQRILKAHRE811 
 812GQRYRVYIVIPLLPGFEGDISTGGGNALQAIMHFNYRTMCRGESSILEQL861 
 862KPELGNKWINYISFCGLRTHAELEGNLVTELIYVHSKLLIADDNTVIIGS911 
 912ANINDRSMLGKRDSEMAVIVQDTETVPSVMDGKEYQAGRFARDLRLECFR961 
 962LVLGYLSDPSEDLQDPVSDKFFKEIWVSTAARNATIYDKVFRCLPNDEVH1011 
1012NLIQLRDFINKPILAKEDALRAEEELRKIRGFLVQFPLYFLSEENLLPSV1061 
1062GTKEAIVPMEVWT1074 
Figure 4: D4 sequence 
CRIII (in red), HKD domain (in pink)  and CT (in green) are conserved regions critical for 
PLD catalytic functions21. D4 binds also RhoA23; PED and RhoA interaction site overlap but 
are not identical24. 
Table 1 
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components. An advantage of this system is that high purity or large amounts of the 
biomolecules are not strictly required25, 26, 27. It combines the use of biosensors with 
Surface Plasmon Resonance (SPR).  
SPR is an optical phenomenon arising in thin metal under conditions of total 
reflection that produces a sharp dip in the intensity of reflected light at a specific 
angle (the resonance angle). The position of this angle depends on several factors, 
including the refractive index of the medium close to the non-illuminated side of the 
metal film. Refractive index is directly correlated to the concentration of dissolved 
material in the medium. By keeping other factors constant, SPR can be used to 
measure changes in the concentration of molecules in a surface layer of solution in 
contact with the sensor surface In Real-time BIA, one of the component (named 
ligand) is covalently attached to a dextran coated gold surface28. A solution of the 
other component (named analyte) is then injected over the surface at continuous 
flow. As molecules from solution bind to the ligand, the resonance angle changes 
and a response is registered (Fig.5).  
 
 
 
In a typical experiment, the analyte is injected over the sensor surface with the 
immobilized ligand, and a full record (named sensorgram) of the progress of the 
biospecific interaction can be obtained by continuously measuring the SPR angle 
versus time.   After the association phase, buffer washes out the analyte and the loss 
of bound analyte from the sensor is also registered (Fig.6).  
Data from the sensorgram can also be used to calculate kinetic and thus 
equilibrium constants25. 
Figure 5: Real-time BIA 
technology 
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1.4 POTE 
Since the publication of the human genome sequence, a new era for cancer 
research has been opened29. Search for Expressed Sequence Tag (EST) in the 
human genome sequence has been made possible with the help of bioinformatics. 
The development of a computer-based screening strategy has allowed the 
identification of several genes that are expressed in prostate cancer30. Using this 
approach, a new gene family has been discovered, POTE, which is selectively 
expressed in normal prostate, testis, ovary and placenta, as well as in prostate 
cancer31. The POTE family consists of at least 11 genes located on chromosomes 2, 
8, 14, 15, 18, 21 and 22. Although POTE function is unknown, the presence of so 
many variants with 90-98% sequence identity indicates selective pressure to 
maintain the gene. POTE family genes (Fig.7) appear to be primate-specific; they 
encode for a highly homologous group of proteins that contains five to seven ankyrin 
repeats and a spectrin domain at its C-terminus, suggesting interaction with the 
cytoskeleton. Preliminary studies have localized POTE to the plasma membrane32. 
 
 
 
 
 
Figure 7:  POTE variants in the genome 
Exons are represented as square boxes. Red boxes denote N-termminal 
repeats, green boxes ankyrin repeats, blue boxes helical C-terminus28. 
Figure 6: A typical sensorgram 
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Recent studies shows that POTE is also expressed in several other different 
cancer types. In particular, POTE expression in breast cancer has been 
investigated33. PCR on cDNAs from breast tissues31 and RT-PCR of RNA from the 
MCF-10A breast cancer cell line33 showed that POTE transcripts are not present in 
these samples. Instead, four out of five breast cancer cell lines express POTE, and 
the variants found in cancer cells are mostly POTE-2α and POTE-2γ (Fig.8).  
 
 
 
 
 
 
 
 
 
Moreover, MCF-10A cells transformed by the oncogenes ErbB-2 and Ras also 
express POTE, suggesting that it is an event that occurs during tumorigenesis33. 
All these findings suggest that POTE may be activated during tumorigenesis in 
many but not all breast cancers, implying that POTE could be used as a specific 
target for breast cancer therapies. 
 
1.5 LENTIVIRAL EXPRESSION SYSTEM 
The lentiviral expression system uses lentivirus to deliver a target gene to 
mammalian cells. A lentivirus is a replication-incompetent, HIV-1 based lentivirus that 
can be used in a wide range of both dividing and non-dividing cells, broadening its 
potential application beyond those of other virus-based retroviral systems.  It can be 
used also for in vivo delivery of the target gene and the presence of multiple features 
designed to enhance the biosafety of the system eases its manipulation34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: POTE expression 
1, no DNA; 2, MCF10A cDNA; 3, MCF-7 cDNA; 4, HTB-30 cDNA; 
5, MDA-MB-231 cDNA; 6,HTB-19 cDNA; 7, HTB-20 cDNA; 8,ZR-
75-1 cDNA 
  1      2     3     4     5       6    7     8 
Figure 9: Production of recombinant 
lentivirus  
 
 
VIRAL SUPERNATANT 
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To generate a recombinant lentiviral stock, the target gene is cloned into an 
expression vector containing all the signals for its expression in mammalian cells as 
well as elements that allow packaging of the construct into virions. The vector and a 
mixture of plasmids, supplying the helper functions as well as structural and 
replication proteins in trans required to produce the lentivirus, are then 
contransfected in HEK293T producer cells. The recombinant lentivirus can be 
harvested in the supernatant after 48 hours, titered and transduced into the 
mammalian cell line of interest (Fig.9). 
Once the lentivirus enters the target cell, viral RNA is reverse-transcribed, 
actively imported to the nucleus and stably integrated in the genome. Once 
integrated, the lentiviral genome is no longer capable of producing packageable viral 
genome35. A stable transduced cell line can be selected using the Blasticidin 
resistance that is introduced with the target gene. 
 
1.6 AIM OF THESIS 
In the study illustrated in this paper, DNA recombinant technology has been 
employed as the starting point for elucidating PED-PLD1 interaction and for both 
expressing and silencing POTE in suitable cell lines. 
To date, very little is known about the PED-PLD1 interaction, which is in some 
way involved in the pathogenesis of type-2 diabetes mellitus. In the present work, 
PED and the D4 domain of PLD1 have been expressed and characterized. Real-time 
BIA has been used to set up an in vitro binding assay, to obtain new elucidations on 
their interaction. Moreover, this assay has been used to screen PED-derived 
antagonists peptides in a competition assay. This experiment had served not only to 
further characterize PED-PLD1 interaction, but also to look for antagonists which 
could be used as pharmacological molecules in the therapy of type 2 diabetes. 
Instead, understanding POTE expression patterns, regulation and its role in 
cancer cells is essential to explore its therapeutic potential. For this reason, a 
recombinant POTE expressing breast cancer cell line has been created, using the 
lentiviral expression system. This system has also been employed to generate 
recombinant virus capable of silencing POTE expression in breast cancer cell lines. 
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2. RESULTS 
 
2.1 PED-D4 INTERACTION 
2.1.1 PED cloning, expression and purification 
PED ORF (kindly provided by Prof. F. Beguinot, Dipartimento di Biologia e 
Patologia Cellulare e Molecolare, Università Federico II di Napoli) was amplified by 
PCR using two primers allowing its cloning in 5 different E. coli pETM expression 
vectors36 (Table 2). 
 
EXPRESSION VECTOR N-TERMINAL TAG SELECTABLE MARKER 
pETM-11 6-His Kan 
pETM-20 6-His+ TrxA Amp 
pETM-30 6-His+ Gst Kan 
pETM-52 6-His+ DsbA Kan 
pETM-60 6-His+ NusA Kan 
 
 
 
Expression of all recombinant proteins is under the control of the T7 promoter 
in these vectors, which contain a TEV recognition site between the protein of interest 
and its fusion partners. Expression levels in the E. coli strain Bl21(DE3) (1mM IPTG, 
3 h @ 37°C), were evaluated through SDS-PAGE analysis of total, soluble and 
micropurified fractions of 1.5 ml of cell cultures. Best results were obtained using the 
recombinant pETM30 (Fig.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further experiments showed that using the strain Bl21(DE3)star it was 
possible to obtain up to 300 mg of PED fused to Gst+His6/ litre of bacterial culture. 
PED+Gst+His6 was purified on a His-trap column and, after dialysis, 
hydrolyzed in the presence of TEV protease. To recover PED alone, the reaction 
mixture was again loaded on a His-trap column: in this case, PED is recovered in the 
flow-through, while fusion partners, undigested protein and TEV protease (that also 
kDa 
150 
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75 
 
50 
 
35 
 
25 
11 12 13 14 15  16 17 18  1  2   3   4   5   6   7    8   9   10  
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50 
 
35 
 
25 
 
15 
 
Figure 10:SDS-PAGE analysis of the expression levels 
1, 11: Perfect Protein Marker; 2, 3, 4: pETM11, total, soluble and micropurified fractions 
(expected protein size: 16.8 kDa); 5, 6, 7: pETM20, total, soluble e micropurified 
fractions (expected protein size: 28.6 kDa); 8, 9, 10: pETM30, total, soluble e 
micropurified fractions (expected protein size: 41.6 kDa); 12, 13, 14: pETM52, total, 
soluble e micropurified fractions (expected protein size: 37.7 kDa); 15, 16, 17: pETM60, 
total, soluble e micropurified fractions (expected protein size: 70.8 kDa); 18: wild-type, 
soluble fraction 
12% 10% 
Table 2 
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has an His-tag at its N-terminus) bind to the column. At this point, PED is about 95% 
pure. 
To obtain grater than 99% purity, PED obtained from the previous step was 
then loaded on a Gst-trap column and the flow-through, after dialysis, eventually 
purified on an anionic exchange column MonoQ HR 5/5 (Fig.11): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 PED characterization  
2.1.2a Mass spectrometry 
 PED molecular weight was determined by LC-MS. 0.5 µg were loaded on a 
BioBasic Column C18 50x2 mm ID and then analyzed by Mass Spectrometry 
(Fig.12). The resulting value is 128 amu higher than the theoretical one: this is due to 
an additional glycine-alanine sequence introduced at the N-terminus during the 
cloning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LC-MS of the trypsin-treated protein also confirmed PED identity (Fig.13). 
 
kDa 
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1     2         3             4  
12% 
Figure 11: PED purification 
1: Perfect Protein Marker; 2: PED+Gst+His6 after hydrolysis in 
presence of TEV protease; 3: Elution after Gst-trap; 4: Elution after 
MonoQ HR 5/5 purification 
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Figure 12: Mass spectrum of recombinant PED 
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2.1.2b 3-dimensional structure 
 Previous NMR experiment had shown that PED has a death-effector domain 
at its N-terminus, characterized by a typical structure of 6 α-helices, while the C-
terminus is unstructurated6. 
To asses the recombinant protein folding, a CD analysis of recombinant PED 
was performed. The result was a spectrum typical of α-helical structures, with a first 
minimum at 208 nm and a second one at 221 nm. This confirms that the protein is 
correctly folded (Fig.14). 
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Figure 13: Mass spectrum of trypsin-treated recombinant PED  
 
Figure 14: CD spectrum of recombinant PED 
PED concentration is 1.7*10-5M in Tris-HCl 50 mM, pH 7.5. 
Temperature is set at  10°C 
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PED stability was also assessed using CD spectroscopy. Thermal 
denaturation of PED was performed, arising the temperature from 10 to 70 °C and 
changes in its response at 222 nm were registered. The result was that PED 
denaturation occurs at a temperature higher than 55°C (Fig.15), asserting that PED 
has a very stable and compact structure.  
 
 
 
 
 
 
 Moreover, PED is promptly refolded after thermal denaturation, as shown 
comparing the CD spectrums of the protein at 10°C, 70°C and then 20°C after 
thermal denaturation (Fig.16). At 70°C, in fact, the protein is totally unfolded, while at 
20°C most of the α-helical structure is recovered. 
 
 
 
 
 
 
 
 
Figure 15: Thermal denaturation of PED, as monitored by CD 
PED concentration is 1.7*10-5M in Tris-HCl 50 mM, pH 7.5. Temperature is 
scanned from 10 to 70°C at λ=222nm 
Figure 16: PED refolding after thermal denaturation 
PED concentration is 1.7*10-5M in Tris-HCl 50 mM, pH 7.5. The 
starting temperature is 10°C (green curve), it is raised to 70°C 
(brown curve), then lowered to 20°C (blue curve) 
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 The state of PED oligomerization was determined by gel filtration. 100 µg of 
PED were loaded on a Superdex75 10/300 GL column, previously calibrated, in 
Sodium phosphate buffer 20mM, NaCl 150 mM, pH 7.5. PED elution volume (11.02 
ml) was the same of a protein with a molecular weight of about 35 kDa, showing its 
dimeric nature. Interaction is not due to the formation of disulfide bridges, since no 
difference was observed by loading PED on a SDS-PAGE with and without reducing 
agents. 
Several attempts to crystallize PED have so far failed; this is probably due to 
the high chain flexibility of the C-terminal end of the protein, that doesn’t allow the 
formation of crystallization nuclei. 
 
2.1.3 D4 cloning, expression and purification 
The D4 domain of hPLD1 was also amplified from a cloning vector kindly 
provided by Prof. F. Beguinot, Dipartimento di Biologia e Patologia Cellulare e 
Molecolare, Università Federico II di Napoli. The expression results with all five 
vectors (see Table 1) were poor but the vector pETM20 in Bl21(DE3)pLysS E.coli 
(0,1mM IPTG, 16h @ 22°C) yielded sufficient protein (1mg/litre of culture) for our 
purposes.  
 Due to the high number of cysteines (5), to suppress the formation of disulfide-
linked aggregates and to obtain reproducible results all purifications had to be 
performed in the presence of TCEP (1mM) containing buffers. However, also in these 
conditions the protein is quite unstable, showing a strong tendency to be degraded. 
Furthermore, any attempt to cleave D4 from its fusion partners failed, so the whole 
protein (named D4+TrxA+His6) was used for all subsequent experiments. 
The fusion protein was purified on His-trap columns, followed by anion 
exchange chromatography on a MonoQ HR 5/5 column. Surprisingly, D4+TrxA+His6 
was eluted at both 220 and 280 mM NaCl (Fig. 17) 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: D4+Trx+His6 anionic exchange chromatography 
10% SDS-PAGE- 1, Perfect protein marker; 2, Input; 3, Fraction 16; 4, 
Fraction 17; 5, Fraction 18; 6, Fraction 19; 7, Fraction 20. The red arrow 
indicates D4+Trx-His6 
D4-Trx-His6 
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2 
1   2    3   4  5  6  7 
kDa
100 
75 
 
50 
 
35 
 
 20 
Other proteins in fractions 18-19 were separated from D4+Trx+His6 by a 
Superdex200 HT 10/30 gel filtration (Fig.18). 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
All proteins were subsequently analyzed by LC-MS. 0,5 µg from each fraction 
were loaded on a Jupiter Column C4 250x2 mm ID for LC-MS analysis. Both proteins 
corresponding to peak 1 of MonoQ HR 5/5 (named D4M) and fractions 10-11 of 
Superdex 200 (named D4D) have a mass corresponding to that expected for 
D4+Trx+His6 (Fig.19). The remaining proteins resulted to be bacterial proteins 
unrelated to D4, as determined by peptide mass fingerprint analysis of peptide 
obtained by trypsin digestion. 
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Figure 18:  Gel filtration analysis of peak 2 eluted from MonoQ HR 5/5 
10 % SDS-PAGE- 1, Perfect protein marker; 2,3 Fractions 4 and 5; 4,5 Fractions 10 and 
11; 6, 7 Fractions 14 and 15 
Figure 19:  Mass spectrum of D4M and D4D 
The resulting mass from MS analysis is about 131 amu lower than the 
theoretical one (55657,4 amu): this is due to the loss of the first 
Methionine during expression, an event that often occurs. 
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2.1.4 D4 dimerization 
 D4M and D4D were analyzed by gel filtration on a Superdex200 HR 10/30 HR 
10/30 column, previously calibrated. The results showed that D4M corresponds to a 
monomeric form, while D4D is mainly dimeric (Fig.20). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
This result was also confirmed by loading D4M and D4D on a 10% native gel. 
 Main peak 
Ve (ml) 
Resulting 
MW (kDa) 
D4M 13,698 112 
D4D 12,424 54 
D4M 
    Monomer 
     Dimer 
Dimer 
Monomer 
D4D 
Figure 20:  Gel filtration analysis of D4M and D4D. 
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The monomeric-dimeric equilibrium was shown to be sensitive to changes in 
the ionic strength of the buffer. Particularly, at high saline concentration the 
monomeric form is preponderant (Fig.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.5 PED-D4 binding 
2.1.5a ELISA assays 
 An ELISA assay was set up to check the binding of D4+Trx+His6 to 
recombinant PED. Preliminarily, anti-PED rabbit serum was dosed against PED 
(Fig.23). 
 
 
 
Figure 22: Effect of ionic strength on D4+Trx+His6 dimerization 
A: Buffer Sodium phosphate 20 mM, NaCl 50 mM, pH7,5; B: Buffer Sodium 
phosphate 20 mM, NaCl 250 mM, pH7,5; C: Buffer Sodium phosphate 20 mM, NaCl 
1 M, pH7,5 
A 
C 
B 
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The assay was performed coating the wells with different concentrations of 
pools of D4M and D4D; then, increasing amounts of PED were added. Detection was 
achieved using 1:10000 dilution of anti-PED serum. The assays confirmed the 
binding of PED to D4+Trx+His6 (Fig.24) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.5b: Surface Plasmon Resonance 
The interaction between PED and D4+Trx+His6 was further assessed by SPR 
using a BIACORE 3000 system. PED was efficiently immobilized on the sensor 
surface, obtaining a signal of about 4000 RU. Solutions of Trx+His6 concentrated up 
to 3,6 µM were first injected at a 30 µl/min flow rate, using HBS buffer, pH 7.4, and 
no interaction was detected. Then increasing concentrations of D4+Trx+His6 from 
different fractions were analyzed. The results were different depending on whether 
D4M and D4D were used: using the dimeric protein, D4D, no binding to immobilized 
Figure 24: ELISA binding assay 
D4+Trx+His6 0,2 µg/ml 
 D4+Trx+His6 2 µg/ml 
D4+Trx+His6 10 µg/ml 
D4+Trx+His6 40 µg/ml 
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Figure 23: Anti-PED serum dosage 
PED 0,2 µg/ml 
 PED 2 µg/ml 
PED 10 µg/ml 
PED 20 µg/ml 
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PED was to detected, while using fractions containing the monomeric D4M, dose-
dependent binding curves were readily observed (Fig.25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D4M (monomeric) binds to PED and has a dissociation constant of 2±1*10-7 M 
(as calculated with the BIAevaluation software). 
 
2.1.6 Competition assay 
The Biacore 3000 system was also used to set up a competition assay to 
identify PED peptides able to compete with D4-PED binding. 
To this aim, PED was hydrolyzed in the presence of trypsin; the reaction was 
stopped by adding PMSF 0,5 mM; LC-MS analysis of the protein confirmed digestion. 
Solutions of D4M were then mixed with solutions of undigested and trypsin-treated 
PED, and injected on the PED-coated chip (Fig.26).  
 
 
D4M 
650 nM; 
1.3 µM 
1.7 µM 
2.6 µM 
 
D4D 
1.8 µM 
3.6 µM 
Figure 25: SPR binding assay 
 RU
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The result was an 80% signal reduction when D4M was mixed with PED in a 
1:4 ratio, while a 1:4 ratio D4M: trypsin-treated PED reduced the signal by 41%, and 
the result was almost the same with a 1:10 ratio (Fig.27).  
 
 
            
 
 
 
 
 
Figure 26: Sensorgrams of PE-D4 competition. 
--- D4M 2µM 
--- D4M 2µM + PED 8 µM 
--- D4M 2µM + trypsin-treated PED 8 µM 
--- D4M 2µM + trypsin-treated PED 20 µM 
 
Figure 27: Sensorgrams of PED competition. 
1 D4M 2µM 
2 D4M 2µM + PED 8 µM 
3 D4M 2µM + trypsin-treated PED 8 µM 
4 D4M 2µM + trypsin-treated PED 20 µM 
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 110 µg (7.2 nmol) of PED were then hydrolyzed in presence of trypsin and 
loaded on a HPLC C18 column for separation. 9 pools of peptides were collected 
(Fig.28). 
 
 
 
Each pool was then lyophilized, resuspended in 100 µl of H2O and 
characterized by LC-MS (Table 3).  
 
POOLS PED PEPTIDES IDENTIFIED BY LC-MS 
F --- 
1 --- 
2 29EDIPSEK35; 108YKDIIR113; 123LAPPPKKA130; 
3 89ISEEDELDTK98; 110DIIR113; 114QPSEEEIIK122 
4 --- 
5 36SEEITTGSAWFSFLESHNK54; 36SEEITTGSAWFSFLESHNKLDK57; 
55LDKDNLSYIEHIFEISR71; 58DNLSYIEHIFEISR71; 72RPDLLTMVVDYR83 
6 -2GAMAEYGTLLQDLTNNITLEDLEQLK24 
 
 
 
 
 
Assuming a total recovery of the protein, concentration of each peptides was 
supposed 72 µM. 20 µl of pools 2, 3, 5 and 6 were used for the competition assay 
with D4M 1 µM, in a final volume of 90 µl (Fig.29). 
Figure 28: HPLC of trypsin-treated PED 
Table 3 
PED numbering starts at -2 because of the GA dipeptide 
introduced during the cloning upstream 1Met. 
 
F 3 2 1 6 5 4 
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Pool 3 and 5 gave a reduced signal, but pool 6, corresponding to peptide -2G-
K24 alone, reduced this signal further to 50% of its original value. 
 
2.2 POTE2γ  
2.2.1 Lentivirus production 
The lentiviral expression system has been used to deliver the gene in the cell 
line of interest. The protocol to produce the lentiviral stock has been optimized to 
obtain the highest viral titre.  
Initially, two different transfection protocols were compared, the BES-Calcium 
phosphate precipitation method and Lipofectamine 2000 transfection procedure 
(Invitrogen protocol). 10 µg of pLenti6/V5-GW/lacZ (Invitrogen) expression vector 
were transfected in HEK 293T cells according to both protocols. 48 hours after 
transfection, the cells were stained with X-gal to check the expression of β-
galactosidase (Fig.30). The BES-Calcium phosphate precipitation method was 
shown to be more effective than the Lipofectamine 2000 transfection procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 30:  X-gal staining 
A: HEK 293T cells, negative control; B: BES-Calcium Phosphate 
precipitation method; C: Lipofectamine 2000 transfection procedure 
 
 
A B C 
Figure 29: Competition assay 
1 D4M 1µM 
2 D4M 1µM + 20 µl pool 2  
3 D4M 1µM + 20 µl pool 3 
4 D4M 1µM + 20 µl pool 5 
5 D4M 1µM + 20 µl pool 6 
 
 28 
POTE2γ was then cloned in an expression vector providing all the signals 
necessary for the expression of the gene in a mammalian cell line; the vector was 
pLenti6/V5-D-Topo (Invitrogen, Fig.31) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To produce the lentiviral stock, 12 100mm-plates of 80% confluent HEK293T 
cells were cotransfected with 3 µg of the expression vector and 9 µg of Virapower 
Packaging Mix (Invitrogen, a mixture of 3 plasmids that provides in trans the 
structural and replicative proteins necessary for the viral packaging of the pLenti 
expression vector). After 18h, the transfection medium was replaced with 10 ml of 
fresh D-MEM medium + Sodium butyrate 10 mM33 and, after further 24 hours, the 
viral supernatant was collected and concentrated.  
The titre of POTE2γ lentiviral stock in HT1080 cells was 9*106 TU/ml (Fig. 32) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
2.2.2 POTE2γ  expression in MCF10A cells 
POTE2γ is expressed in many breast cancer cell lines; moreover, its 
expression is induced in normal breast epithelial cells transfected with oncogenes. 
These findings suggest that POTE2γ expression is an event that occurs during 
 
Figure 32:  Titration of POTE2γ lentiviral stock 
Dilutions of the viral stock are reported in red. 
0  10-2 
 10-4  10-5  10
-6 
 10-3 
Figure 31:  pLenti6/V5-Topo expression vector 
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tumorigenesis.  To evaluate the effect of POTE2γ expression, it was decided to stably 
express this gene in a non-tumorgenic breast epithelial cell line, MCF10A (ATCC 
Number: CRL-10317).  
To select for stably transduced cells, it was first necessary to perform a kill 
curve experiment, to determine the minimum concentration of Blasticidin required to 
kill untransduced cells within 10-14 days after antibiotic addition. For MCF10A cells, 
the minimum concentration was 6 µg/ml.  
MCF10A cells were infected with an MOI (Multiplicity Of Infection) of 1 and 
then selected. To confirm the integration of POTE2γ into the genome of the selected 
cells, RT-PCR was performed. Two primers specific for POTE2γ were used. The 
result was positive for Blasticidin selected MCF10A cells, where an amplification 
product of 386 bp was observable on agarose gel, in contrast to the negative result 
for wild-type MCF10A (Fig. 33). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
2.2.3 RNA interference 
To further characterize the effect of POTE expression, it was decided to 
silence its expression using RNA interference (RNAi) combined with the lentiviral 
expression system.  
RNAi is a phenomenon by which dsRNA induces a powerful and specific 
inhibition of eukaryotic gene expression via mRNA degradation, using short hairpin 
RNA (shRNA). shRNAs are an artificial class of RNAs that contain the following 
structural features: a short sequence of 19-29 nucleotides derived from the target 
gene, followed by a 4-15 nucleotides loop and then a reverse complement of the 
initial target sequence. When a specific shRNA is expressed in an eukaryotic cell 
line, mRNA of the target gene is degraded, silencing its expression. The lentivirus 
system was used to deliver the sequence coding for shRNA into the cells. 
Initially, the silencing protocol was optimized for the target gene lamin 
(Genebank accession number: BC014507). A pair of complementary, single-strand 
DNA oligonucleotides, designed for lamin silencing (from Invitrogen), was 
synthesized and used with Invitrogen Block-it Lentiviral Expression System to 
generate the expression vector pLenti6/Block-It-shLam. this vector was employed to 
generate a lentiviral stock according to the procedure previously optimized. The titer 
of sh-lamin lentivirus was 5*107 TU/ml. 
MCF7, a breast carcinoma cell line (ATCC Number: HTB-22), was chosen as 
the target cell line for lamin silencing. A kill curve experiment indicated 8 µg/ml as the 
best Blasticidin concentration for selection of transduced cells. So, MCF7 cells were 
Figure 33 : RT-PCR 
1, Ladder Marker; 2, Negative control, T444-T445 primers; 3, MCF10A cDNA, T444-T445 primers; 
4, MCF10A/POTE2γ cDNA, T444-T445; 5, Negative control,  Actin primers; 6, MCF10A cDNA, Actin 
primers; 7, MCF10A/POTE2γ cDNA, Actin primers 
1   2    3   4   5   6    7 
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infected with sh-lamin lentivirus at MOI=5 and selected. 107 wild-type and 
recombinant cells were lyzed and analysed by Western Blotting (Fig.34). 
 
 
  
 
 
 
 
 
 
 
 
 
 
All three lamin variants are no longer expressed in sh-Lamin transduced cells, 
indicating that the gene was silenced.  
Since the silencing of lamin in MCF7 using lentivirus as the delivery system of 
shRNA worked, sh-POTE lentivirus was prepared. A target sequence was identified 
with the help of Block-it RNAi Designer, a software provided by Invitrigen (Fig.35). 
Two complementary ss-DNA oligonucleotides containing the target sequence were 
prepared and used to produce sh-POTE lentivirus; the titre was 1,4*106. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1    2        3    4  
 
Figure 34:  Western blot analysis of lamin silencing 
1, MCF7 lysate, 10 µg; 2, MCF7 lysate, 35 µg; 3, MCF7-shLamin 
lysate, 10 µg; 4, MCF7-shLamin lysate, 35 µg 
 
  1ATGGTGGTTGAGGTTGATTCCATGCCGGCTGCCTCTTCTGTGAAGAAGCC50 
 51ATTTGGTCTCAGGAGCAAGATGGGCAAGTGGTGCTGCCGTTGCTTCCCCT100 
101GCTACAGGGAGAGCGGCAAGAGCAACGTGGGCACTTCTGGAGACCACGAC151 
Figure 35:  Target sequence for POTE2γ silencing 
Only the first 150 nucleotides of POTE coding sequence have been 
reported; target sequence for RNAi are in red. 
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3. CONCLUSIONS 
 
 Although several lines of evidence indicate that the PED-PLD1 interaction is 
involved in impairment of insulin-stimulated transport in type 2 diabetes, very little is 
known about this interaction. 
 In the present work, both PED and the D4 domain of PLD1, which is the 
shortest region still able to bind to PED, were cloned in a bacterial expression vector, 
expressed in E. coli and purified. 
 Hydrolysis in the presence of TEV protease enabled cleavage of PED from its 
fusion partners and its characterization it. LC-MS of the entire protein and  peptide 
mass fingerprinting confirmed its identity. PED α-helical structure resulted very 
stable, as seen with CD analysis and thermal denaturation. 
Reducing conditions were used in all D4 manipulations, to avoid the formation 
of aggregates. Two different isoforms of D4, monomeric (D4M) and dimeric (D4D), 
were isolated. The intermolecular interaction in the dimeric form is not due to the 
formation of disulfide bonds, since reducing conditions were always employed. It is 
rather dependent on ionic strength, since at high saline concentration the equilibrium 
was shifted to the monomeric form.  
Real-time BIA technology showed that PED only interacts with the monomeric 
form of D4; moreover, using trypsin-derived peptides in a competition assay, peptide 
1-24 of PED resulted to be a strong competitor for D4 binding. 
PLD dimerization is an event whose biological significance is unknown. PLD 
dimers might not be active: dimerization might hide the catalytic site of PLD, or 
dimers might be located at the wrong cellular site, because dimerization might 
occlude certain domains that specify localization of the monomer. Moreover, PLD 
domain(s) involved in this interaction have not been defined. 
D4 is the C-terminal region of hPLD1 that contains one of the two HKD 
domains (the other is in the N-terminal region) whose dimerization is required for 
PLD activity16,17. In the present study, it has been shown that D4 exists both as a 
monomer and dimer; these findings suggest that PLD might dimerize through an 
intermolecular interaction of D4 domains from two different PLDs. The result might be 
an inactive dimer, where the two N- and C-halves of each subunit do not interact to 
constitute the catalytic site.  
PED only interacts with the monomeric form of D4. This might mean that in 
vivo PED binds the C-terminus of PLD1 during translation, stabilizing the active 
monomer and avoiding dimerization. Thus, in PED overexpressing cells, the 
concentration of the active monomeric form will be higher than in normal cells, 
resulting in higher PLD activity, and, subsequently, in impaired insulin-stimulated 
glucose transport. 
Phosphorylation is not required for PED-PLD1 interaction, since PED-D4 
binding was revealed with recombinant proteins expressed in bacteria. Using SPR 
technology to set up a competition assay, the D4-interacting region of PED has been 
identified. It consists of the first 24 amino acids of PED, corresponding to the first two 
helices of the DED. No phosphorylation site is present, and this explains why it is not 
involved in the PED-PLD1 interaction. Previous experiments localized the PED D4-
binding site in region 53-112: from the competition assay, several peptides derived 
from this region competed with D4 for PED binding, but not as much as the 1-24 
region.  
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Further experiments are ongoing to identify PED D4-binding site. Identification 
of these peptides implies several consequences. They can be used to model the 
PED-D4 interface, providing important insights in the elucidation of interaction details. 
They might be used in vivo to further characterize the effect of PED-D4 on glucose 
transport. Most importantly, these peptides might be used for pharmaceutical 
applications: block of PED-PLD in PED overexpressing cells might restore normal 
insulin-stimulated glucose transport.  
 
Instead, the interest in POTE2γ as a specific target in breast cancer therapies, 
has aroused interest in characterizing the effects of both its expression and its 
silencing.  
The lentivirus system was used as vehicle for the generation of a stable 
POTE2γ expressing cell line. A complete protocol for high throughput production of 
lentiviral stock was preliminarily set up, evaluating different cell transfection methods. 
MCF10A cells (a non-tumorigenic breast epithelial cell line) was infected with 
POTE2γ recombinant lentiviruses to evaluate the effect of POTE expression in a 
breast cell line that doesn’t express this gene. RT-PCR confirmed the insertion of this 
gene in the host cell line. Experiments are ongoing to analyze changes in gene 
expression by cDNA microarray 
The lentiviral expression system was also found to be a powerful system for 
the expression of sh-RNA for gene silencing. It was able to efficiently silence a target 
gene, lamin A/C, in MCF7 cells (a breast cancer cell line). Recombinant sh-POTE2γ 
lentiviruses were prepared, to evaluate the effect of POTE silencing in a cell line 
usually expressing this gene. 
Anti-POTE antibodies have been prepared, and are currently being 
characterized.  As soon as they become available, MCF7 cells will be infected with 
sh-POTE2γ and the effect of silencing in the cell line will be evaluated. 
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4. EXPERIMENTAL PROCEDURES 
 
4.1 MATERIALS AND INSTRUMENTS 
PED and D4 cDNA and anti-PED rabbit serum were kindly provided by Prof. F. 
Beguinot, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università 
Federico II (Napoli. Italy). pETM vectors are from EMBL (Heidelberg, Germany). 
Oligonucleotides were synthesized by Sigma-Genosys (Sigma-Aldrich,  Milano, Italy). 
Pfu DNA polymerase is from Stratagene (Milano, Italy). Restriction enzymes are from 
New England Biolabs (Milano, Italy). All molecular biology kits and Ni-NTA Magnetic 
Agarose Beads are from Qiagen (Milano, Italy) Escherichia coli bacterial strains are 
from Novagen (Milano, Italy), except for TOP10F’ that are from Invitrogen (Milano, 
Italy). IPTG is from Inalco (Milano, Italy). Reagents for bacterial medium are from 
Becton-Dickenson (Milano, Italy). All reagents for native gels and SDS-PAGE, all 
chromatography columns and AKTA FPLC are from Pharmacia Amersham 
Biosciences (Milano, Italy). GAR-HRP antibody is from Bio-Rad (CA, USA); BIAcore 
system and reagents were from Pharmacia Biosensor AB (Uppsala, Sweden). All 
other reagents and chemicals are commercially available by Sigma-Aldrich or Fluka 
(Bucks, Switzerland). 
 Growth media for HEK293T, HT1080 and MCF7 cells (DMEM,Dulbecco’s 
modified Eagle’s medium+10 % FBS +1% Penicilin G sodium+2 mM L-glutamine) and 
for MCF10A cells (MEBM, Mammary Epithelium Basal Medium+MEGM Singlequots) 
are from Cambrex (AZ, USA). All Lentiviral vectrors and reagents are from Invitrogen.  
PCR Sprint is from Hybaid; all centrifuges are from Eppendorf (Milano, Italy), 
except for Allegra 6R and Avant J-25 centrifuges, from Beckman Coulter (Milano, 
Italy),; UV/Visible spectrophotometer DU530 is from Beckman Coulter (Milano, Italy); 
bacterial incubators are from Infors Multitron; Sonicator 3000 is from Misonix; 
Microplate Reader Model 680 is from Biorad (CA, USA). 
 
4.2 PED AND D4 CLONING 
PED was PCR amplified with primers PEDFW (5’- CGCGCGCCATGGCTGAG 
TACGGGACCCTCCT-3’) and PEDRV (5’-CGCGCGGATCCTTATCAGGCCTTCTTC 
GGTGGGGGAG-3’), using Pfu DNA polymerase and Tm=54°C. Amplified DNA was 
purified with QIAquick PCR Purification Kit and digested with NcoI, again purified with 
QIAquick PCR Purification Kit and then digested with BamHI enzyme. Double 
digested fragment was extracted from 1,2% agarose gel using QIAquick Gel 
Extraction KIT and ligated into pETM vectors, previously digested and 
dephosphorylated. Ligation products were electroporated into TOP10F’ and 
recombinant colonies were selected by PCR; expression vectors from positive clones 
were isolated using QIAprepSpin Miniprep kit.  
D4 was PCR amplified with primers D4FW (5’-GCGCGCGAAGACCCATGGG 
GTCCCTTTCTTATCCTTTTCTGCTT-3’) and D4RV (5’-CGCGCGCTCGAGTCATTA 
TTAAGTCCAAACCTCCATGGGCACTATG-3’) and then double digested with BbsI 
and XhoI enzymes. Recombinant expression vectors were isolated as described for 
PED expression vectors. 
 
4.3 PED AND D4 EXPRESSION SCREENING 
100 ng of expression vector were chemically transformed in competent cells. 
Two colonies were grown in LB medium o/n at 37°C, then diluted to 0,06 OD/ml and 
induced with IPTG when the culture was grown to 0,6 OD/ml. After 16h at 22°C, 1,5 
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ml of bacterial culture was harvested, lyzed and purified on Ni-NTA Magnetic 
Agarose Beads (following QIAgen protocol). Magnetic beads are resuspended in 10 
µl of SDS-Loading buffer (Tris-HCl 50 mM, SDS 1%, blue bromophenol 0.1%, 
glycerol 10%, pH 6.8) and analyzed on SDS-PAGE together with 10 µl of total and 
soluble fractions of the lysates. 
A first screening was done by transforming all 5 pETM expression vectors (see 
Table 1) in Bl21(DE3) cells, and inducing with 1 mM IPTG. After having chosen the 
best expression vector, results with different E. coli strains were evaluated 
(Bl21(DE3)pLyS, Rosetta(DE3), Rosetta(DE3)pLysS, C41(DE3), C43(DE3), Bl21star 
(DE3), Bl21star(DE3)pLysS, Bl21(DE3)RIP, Bl21(DE3)RIL) and optimal 
concentration of IPTG was determined.  
For PED, a further experiment showed that the yield was the same by inducing 
16 h at 22°C or 3h at 37°C. 
 
4.4 PED PURIFICATION 
100 ml of bacterial culture were resuspended in 4 ml of Phosphate buffer 20 
mM, NaCl 500mM, PMSF 1mM, Triton 0.05%, Lysozyme 1 µg/ml, pH7.4, left for 30’ 
at RT and then sonicated for 2 minutes (20’’on, 10’’ off). Lysate was then centrifuged 
for 20’ at 4°C at 18 krpm and the soluble fraction was loaded on a His-trap Column, 
previously equilibrated with Buffer A (Sodium-phosphate buffer 20 mM, NaCl 500mM, 
pH7.4). PED+Gst+His6 was purified with the following protocol: 
 
 
 
 
 
Purified protein was dialysed against Phosphate buffer 20 mM, NaCl 150mM, 
pH 7.4 and hydrolysed in the presence of 0,01 mg TEV protease (expressed and 
purified in our laboratories) for each mg of PED, DTT 1mM, EDTA 0,5mM, for 16 h at 
30°C.  
Digested PED was loaded on a His-trap Column, previously equilibrated in 
Sodium phosphate buffer 20 mM, NaCl 150mM, pH 7,4, and PED was recovered in 
the flow-through. 
If necessary, PED was further loaded on a Gst-trap column, recovered in the 
flow-through, dialysed against Tris-HCl 20 mM, pH 7,5 (Buffer C) and eventually 
purified on a MonoQ column: 
 
 
 
 
 
PED was eluted at 7% B (70 mM NaCl).  
 
4.5 D4 PURIFICATION 
200 ml of bacterial pellet was lyzed in 20 ml of Tris-HCl 50 mM, NaCl 200 mM, 
Imidazole 20 mM, PMSF 1 mM, Triton X-100 0,25%, Lysozime 1 µg/ml, TCEP 1 mM, 
pH 7,5 for 30’ at RT. Then, it was sonicated for 6 minutes (20’’ on, 20’’ off), 
centrifuged 20’ at 4°C at 15 krpm. The soluble fraction was loaded on a His-trap 
column and purified according to the following protocol: 
 
 CV % BUFFER B  
(Buffer A + Imidazole 500mM, pH 7.4) 
WASH 15 12 
ELUTION 5 60 
 CV % BUFFER D  
(Tris-HCl 50 mM, NaCl 1M, pH 7,5) 
WASH 2 0 
GRADIENT 10 0 to 50% 
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BUFFER 1: Tris-HCl 50 mM, NaCl 200 mM, Imidazole 20 mM, TCEP 1 mM, pH 7,5 
BUFFER 2: Tris-HCl 50 mM, NaCl 200 mM, Imidazole 500 mM, TCEP 1 mM, pH 7,5 
 
 
 
 
 
2 ml of D4+TrxA+His6 from His-trap were diluted with 18 ml of Buffer 3 (Tris-
HCl 50 mM, TCEP 1 mM, pH 7,5), loaded on a MonoQ column and purified 
according to the the following protocol: 
 
 
 
 
D4M and D4D were separated using a Superdex200 column, in TrisHCl 50 
mM, NaCl 250 mM, TCEP 1 mM, pH 7,5. 
 
4.6 PED AND D4 CHARACTERIZATIONS 
LC-MS was performed using 5 µl of a 0.1 mg/ml sample and a LCQ DCA XP 
Ion Trap spectrometer (ThermoElectron, Milan, Italy). This was equipped on OPTON 
ESI source (operating at a needle voltage of 4.2 kV and a temperature of 320 °C) 
and a complete Surveyor HPLC system (including a MS pump, an autosampler and a 
photo diode array [PDA]. Analyses were performed using a narrow bore 250x2 mm 
C4 Jupiter column, 300 A, 3 µm (Phenomenex) and eluting with H2O/0.08%TFA (A) 
and CH3CN/0.05% TFA (B) gradients: 
 
TIME (min) % B 
0 30 
6 30 
35 70 
36 95 
41 95 
42 30 
 
During this time, the sample tray was kept at 20°C, whereas the column was 
kept at 25°C. Mass spectra were recorded continuously at mass intervals of 400-
2000 amu in positive mode (LC-MS, condition 1). Multicharge spectra were then 
deconvoluted using the BioMass program implemented in the Bioworks 3.1 package 
provided by the manufacturer. Mass calibration was performed automatically by 
means of selected multiple charged ions, in the presence of a calibrant (Ultramark, 
ThermoElectron). All masses were reported as average values.  
PED proteolysis was performed by incubation with TPCK-treated trypsin 
(Sigma-aldrich, Milan) at an enzyme:substrate ratio of 1:100 in 50 mM Tris-HCl 
pH7.5. LC-MS was performed as previously described, eluting with H2O/0.08%TFA 
(A) and CH3CN/0.05% TFA (B) gradient: 
 
 
 
 CV % BUFFER 2 
WASH 10 0 
ELUTION 5 36 
 CV % BUFFER 4  
(Tris-HCl 50 mM, NaCl 1 M, TCEP 1 mM, pH 7,5) 
WASH 5 0 
ELUTION 20 0 to100 
 36 
 
 
 
 
 
 
 
 
 
 
Mass spectra were recorded continuously at mass intervals of 400-2000 amu, 
in positive mode and Data-Dependent Analysis (DDA) in order to fragment the eluted 
peptides and obtain sequence information. Fragmentation was induced on selected 
ions from 400 to 1200 amu, with a fixed 35% of total radio-frequency energy. 
CD spectra were obtained on a Jasco J-715 dichrograph, calibrated at 290 nm 
with an aqueous solution of D(+)-10-canphor sulphonic acid. Data were collected at 
0.2 nm intervals with a 20 nm min-1 scan speed, a 2 nm bandwidth and a 16 s 
response, from 260 to 190 nm. 
 
4.7 SUPERDEX75 AND SUPERDEX200 CALIBRATIONS 
Superdex75 column was calibrated using the following standard proteins in 
Sodium-phosphate buffer 20 mM, NaCl 150mM, pH 7.5 (V0 is 7,7 ml; Vt is 24 ml): 
 
PROTEIN MOLECULAR 
WEIGHT (kDa) 
logMW ELUITION 
VOLUME (Ve, ml) 
Kav 
(Ve-V0)//Vt-V0) 
BSA 66 1,82 9,3 0,1 
OVALBUMIN 44 1,64 10,3 0,159 
CARBONIC ANIDRASE 29 1,46 11,6 0,239 
CHYMOTRYPSINOGEN 23 1,36 12,3 0,279 
RIBONUCLEASE 13 1,11 12,9 0,315 
C CYTOCHROM 12,4 1,09 13,4 0,346 
 
 
 
 
 
 
 
 
 
 
The resulting calibration curve is y= -3,02x+2,13 (R2=0,97). 
For Superdex200, the following standards were run in Sodium-phosphate 
buffer 20 mM, NaCl 150mM, pH 7,5 (V0 is 7,1 ml; Vt is 24 ml): 
 
PROTEIN MOLECULAR WEIGHT 
(kDa) 
logMW ELUITION VOLUME 
(Ve, ml) 
Kav 
(Ve-V0)//Vt-V0) 
FERRITINE 460 2,66 9,7 0,154 
CATALASE 206 2,31 11,5 0,262 
ALDOLASE 170 2,23 11,9 0,283 
TRANSFERRIN 81 1,91 12,9 0,343 
BSA 66 1,82 13 0,347 
TIME (min) % B 
0 5 
3 5 
68 70 
70 90 
80 90 
82 5 
90 5 
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OVALBUMIN 43 1,64 14,1 0,415 
CARBONIC 
ANIDRASE 
29 1,46 15,4 0,489 
C CYTOCHROM 12,4 1,09 16,8 0,574 
 
The resulting calibration curve is y= -3,76x+3,24 (R2=0,99). 
 
4.8 ELISA ASSAYS 
To dose anti-PED serum, PED solutions at different concentrations were used 
to coat microtitre wells for 1h at 37°C. The wells were then blocked for 1 h at 37°C 
with 1% BSA in PBS. Different dilutions of anti-PED rabbit serum were added and 
incubated for 1h at 37°C. Interaction was revealed by adding 1:5000 GAR-HRP 
antibodies (1h at 37°C) and staining with Sigma Fast. Each passage was followed by 
an extensive wash with PBS+0,2% Tween20. 
To detect PED-D4 interaction, different concentrations of D4+TrxA+His6 
solutions in PBS were coated on the wells over night at 4°C; after an extensive wash 
with PBS+0,2% Tween 20, the wells were blocked with 1% BSA in PBS for 1 h at 
37°C. After washing, increasingly concentrated solutions of PED were added and 
incubated for 1h at 37°C. After washing, 1:10000 dilution in PBS of anti-PED rabbit 
serum were added and the plate was left for 1h at 37°C. GAR-HRP was used for 
revelation as previously described. 
 
4.9 PED COATING ON SENSOR SURFACE 
A CM5 sensor chip was used to bind PED using the standard amine coupling 
procedure as described by the manufacturer’s instructions. 30 µl of a N-hydroxy-
succinimide and N-ethyl-N’-(dimethyl-aminopropyl)-carbodiimide mixture were 
injected at a flow rate of 5 µl/min to activate the sensor surface, followed by 30, 25 
and 15 µl injections of PED diluted to 0,1 mg/ml in acetate buffer pH 4.0. Unreacted 
activated groups were blocked by a 15 µl injection of ethanolammine. 
Binding assays were carried at a flow rate of 30 µl/min. 
 
4.10 PREPARATION OF PED PEPTIDES 
PED was hydrolyzed using 1:100=enzyme:substrate of TPCK-treated Trypsin 
(Sigma-Aldrich, Milan), 16h at 37°C. 
Preparative RP-HPLC were carried out on a Shimadzu LC-8A, equipped with 
a SPD-M10 AV detector on a Phenomenex Jupiter C18 column (1 × 25 cm; 10 µm) 
with H2O/0.1%TFA (A) and CH3CN/0.1% TFA (B). The gradient used for purification 
was 5 to 70% B in 60min, at a flow rate of 4 ml/min. 
LC-MS of pools was performed as previously described, using gradients: 
 Pools F-1-2-3 
TIME (min) % B 
0 1 
5 1 
40 30 
43 95 
48 95 
49 1 
54 1 
Pools 4-5-6 
TIME (min) % B 
0 5 
3 5 
33 65 
35 95 
40 95 
41 5 
45 5 
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4.11 HEK293T CELL TRANSFECTION WITH pLenti6/V5-GW/lacZ 
Poly-lysine precoated plates were each seeded with 3x106 HEK293T cells and 
cultured with 10 ml of fresh growth media at 37oC, 5% CO2. After 16 h, 10 µg of DNA 
were diluted to a final volume of 450 µl with sterile TE buffer (10 mM Tris-HCl pH 
8.0+1mM EDTA). 50 µl of 2.5 M CaCl2 was added and solution was mixed. The 500 
µl of DNA solution were slowly added to 500 µl of 2X BBS (BES-Buffered Saline 2X: 
NaCl 280 mM; Na2HPO4 1.5 mM; BES 50 mM, pH 6.95). Incubation at RT for 15’ 
allowed the Calcium Phosphate –DNA complex to form. The calcium Phosphate-
DNA mixture was added drop-wise to cultured cells and incubated at 37oC, 3% CO2. 
After a further 16h, the transfection medium was removed and 10 ml of fresh growth 
medium were added and left at 37oC, 5% CO2. After 24 h, cells were checked for 
expression.  
 
4.12 X-GAL STAINING 
Cells were washed with PBS and then 4% formic acid in PBS was added. 
After 20’ at RT, 2 ml of X-gal solution (Potassium Ferricyanide 5mM, Potassium 
Ferrocyanide 5mM, 1mM MgCl2, x-gal 500 µg/ml, in PBS) were added. The stain was 
visible after 2 h at 37°C. 
 
4.13 CRYSTAL VIOLET STAINING FOR BLASTICIDIN RESISTANT 
COLONIES 
Cells were washed with PBS and fixed in 10% Neutral Buffered Solution for 
30’. Cells were washed again with PBS, 1% Crystal Violet was added and, after 30’ 
at RT, cells were washed with PBS until PBS is clear. 
 
4.14 VIRUS PRODUCTION  
12 poly-lysine precoated 100mm-plate were each seeded with 3x106 
HEK293T cells and cultured with 10 ml of fresh growth media at 37oC, 5% CO2, o/n. 
Cells should be 70-80% confluent and evenly distributed at the time of transfection. 
For each plate, 3 µg of expression plasmid were mixed with 9 µl of Virapower 
Packaging Mix and diluted to a final volume of 450 µl with sterile TE buffer (10 mM 
Tris pH 8.0+1mM EDTA). 50 µl of 2.5 M CaCl2 was added and mixed. The 500 µl of 
DNA solution was slowly added to 500 µl of BBS 2X (BES-Buffered Saline 2X: NaCl 
280 mM; Na2HPO4 1.5 mM; BES 50 mM, pH 6.95) and after 15 min the mixture was 
added drop-wise to cultured cells and incubated at 37oC, 3% CO2. After 16 h, the 
transfection medium was removed and 10 ml of fresh growth medium+100 µl of 
Sodium butyrate 1M (final concentration 10 mM) were added. After a further 16 h at 
37oC, 5% CO2, the viral supernatant was harvested, centrifuged at 1000 rpm for 3 
min and passed through a 0.45 µm filter. Filtered supernatant was concentrated at 26 
krpm for 2.5 hrs at 20oC. Viral pellets were resuspended in 1 ml of PBS. Viral stocks 
were frozen in aliquots at -80oC. 
 
4.15 LENTIVIRAL STOCK TITRATION 
Each well of a 6-well plate was seeded with 2x105 HT1080 cells in 2 ml of 
growth medium and incubated o/n, 37oC, 5% CO2. Next day, 10-fold serial dilutions, 
ranging from 10-2 to 10-7, of the lentiviral stock solution were prepared into growth 
medium to a final volume of 1 ml. Medium from the cells was removed and, after 
mixing, each dilution was added to one well of cells. After 16 h at 37oC, 5% CO2, the 
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media containing virus was removed and replaced with 2 ml of fresh growth medium. 
The following day, the medium was exchanged with fresh medium + 4 µg/ml 
Blasticidin; then, every 2-3 days, medium was changed with fresh medium + 
Blasticidin. After 10-12 days of selection, the cells were stained with Crystal violet 
solution. 
 
4.16 RT-PCR 
RNA was extracted from 106 cells with 1ml of TRIzol reagent (Gibco BRL) and 
resuspended in 10 µl of dH2O. 11 µl were used to synthesize cDNA using First-
Strand cDNA Synthesis Kit (Amersham Biosciences). 2 µl were used for a PCR 
reaction with oligonucleotides T444 (5’-CAA TGC CAG GAA GAT GAA TGT GCG-3’) 
and T445 (5’-TCT CTG GCC GTC TGT CCA GAT AGAT-3’), Tm=65°C. Actin 
amplification was used as positive control. 
 
4.17 WESTERN BLOT 
107 cells were suspended in 400 µl of Tris-HCl 50 mM, PMSF 1 mM, 4 µg/ml 
Aprotinin, pH7.4 and sonicated for 2’(10” on, 10” off). Then 20 µl of Tris-HCl 50 mM, 
DNAse 1 mg/ml, RNAse 250 µg/ml, MgCl2 50 mM, pH 7.5 were added and, after 30’ 
at RT, 50 µl of TCA were added. After 20’ incubation on ice, lysate was centrifuged at 
1500 rpm at 4°c for 10’, supernatant was removed and the pellet was washed twice 
with 1 ml of Acetone. The pellet was resuspended in 320 µl of Urea 9M, Triton-X100 
2%, β-mercaptoethanol 5%, then 80 µl of 10% LDS and 0,1 % BPB were added. 
Samples were run on SDS-PAGE and then transferred to a PVDF membrane for 4 h 
at 30V at 4°C with constant stirring.  The membrane was blocked for 16 h at 4°C with 
1% Western Blocking Reagent (Roche) in TBS (Tris-HCl 50 mM, NaCl 150 mM, pH 
7.5), then incubated with 1:1000 dilution in TBS of Purified Mouse Anti-lamin A/C 
Mouse Antibody (BD Transduction Laboratories). The membrane was then washed 
twice with TBST (TBS+0.1 % Tween20) and twice with 0.5% Western Blocking 
Reagent in TBS. 1:30 dilution of Alp-goat Anti Mouse IgG’s in TBS+0.5% Western 
Blocking Reagent was added and, after 1 h at RT, the membrane was extensively 
washed with TBST. 1-step NBT/BCIP solution was used to stain the membrane. 
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4. ABBREVIATIONS 
 
 
 
 
β-MERCAPOTETHANOL 2-mercaptoethanol 
ATCC American Type Culture Collection 
BES N,N-Bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid 
BP Base Pair 
BSA Bovine Serum Albumin                
CD  Circular Dichroism 
cDNA Complementary DNA 
CV                Column Volume 
D4D Dimeric D4 
D4M Monomeric D4 
DAG Diacylglycerol 
DED Death Effector Domain 
D-MEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic Acid 
DNAse Deoxyribonuclease 
dsRNA Double Stranded RNA 
EDTA         Ethylenediaminetetraacetic Acid 
EST Expressed Sequence Tag 
FBS Fetal Bovin Serum 
FPLC         Fast Protein Liquid Chromatography 
GAR-HRP Goat- Anti Rabbit Horseradish 
Peroxidase 
GST   Glutathion S-transferase 
HBS 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 
3 mM EDTA, 0.005% Surfactant P20 
His Histidin 
HIV Human Immunodeficiency Virus 
IPTG   Isopropyl-b-D-Thiogalactopyranoside 
lacZ β-galactosidase 
LB                Bacto-triptone 10 g/l, Yeast Extract 5 
g/l, NaCl 10 g/l 
LC-MS         Liquid Chromatography- Mass 
Spectrometry 
MOI Multiplicity Of Infection 
NMR Nuclear Magnetic Resonance 
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O.D. Optical Density 
ORF Open Reading Frame 
PBS   Phosphate-Buffered Saline Buffer 
PCR   Polymerase Chain Reaction 
PEA15 Phosphoprotein Expressed in Astrocites 
15 
PED Phosphoprotein Enriched in Diabetes 
PKC Protein Kinase C 
PLD1 Phospholipase 1 
PMSF          Phenylmethylsulphonylfluoride 
POTE Prostate, Ovary, Testis Expressed  
gene 
PVDF PolyVinylidine DiFluoride 
RNA Ribonucleic Acid 
RNAi RNA interference 
RNAse Ribonuclease 
RP-HPLC:  Reverse Phase-High Performance 
Liquid Cromatography 
RT Room Temperature 
RT-PCR Reverse Transcriptase-Polymerase 
Chain Reaction 
RU Reflecting Units 
SDS              Dodecylsolphate Sodium 
shRNA Short Hairpin RNA 
SPR Surface Plasmon Resonance 
TBS TrisHCl 50 mM, NaCl 150 mM, pH 7.5 
TBST TBS+0.1 % Tween20 
TCEP Tris(2-carboxyethyl)phosphine 
hydrochloride 
TEV   Tobacco Etch Virus 
TFA    Triflouroacetic Acid 
Tris-HCl 2-Amino-2-(hydroxymethyl)-1,3-
propanediol, hydrochloride 
TrxA ThioredoxinA 
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Introduction:PED/PEA (Phosphoprotein Enriched in Diabetes or in Astrocytes) or 
PED is a ubiquitously expressed 15 kDa cytosolic protein with recognized multiple 
functions. It has been indeed demonstrated that PED has broad proapoptotic 
properties (1) and, by altering insulin secretion, has a proven implication in diabetes 
(2). In cultured cells and in transgenic mice, PED overexpression induces insulin-
resistance and impairs glucose tolerance. Recent evidence indicates that increased 
interaction of PED with Phospholipase D1 (PLD1) is a key event leading to these 
abnormalities in vivo and that this interaction is mediated by a large, C-terminal 
domain of PLDI comprising residues 712-1070 (3). We have prepared PED and a 
D4-fusion protein containing tioredoxin (Trx) at the N-terminaI side to investigate 
protein structures and to set up a binding assay for the screening of potential 
antagonists. The two proteins have been purified and refolded and the recognition 
properties bave been characterized by ELISA assays and by Surface Plasmon 
Resonance. 
Result and Discussion: ped was cloned in a pETM30 vector and expressed in a 
BL21(DE3)star E.coli strain. Expression gave very high levels of the fusion protein 
GST-His6-PED. After a first step of purification on a His-trap column, the GST-His6 
portion was c1eaved and PED purified using again a His-trap column followed by a 
further anion exchange step on a MonoQ column. Mass spectrometry analysis of the 
entire and trypsin-treated protein confirmed protein identity, whereas a 
characterization by CD spectroscopy showed, as expected, that the protein had a all-
alpha secondary structure (4). D4 was cloned in several vectors with different tags 
and several strains of E. coli were tested to optimize the expression of the fusion 
protein (MW about 56 kDa). Optimal results were achieved using the pETM20 vector 
in the BL21(DE3)pLysS strain. Preliminary purification attempts of the resulting 
protein, Trx-His6-D4, gave poorly reproducible results, likely due to aggregation 
events associated to the high number of cysteines in the D4 domain. Remarkable 
improvements were achieved by carrying out the purification in a TCEP-containing 
buffer (1 mM). The fusion protein was then purified on a His-trap column, followed by 
an anionic exchange chromatography step. Attempts to cleave the tag protein with 
TEV protease were unfruitful, as the amount of cut protein was invariably very low. 
The fusion protein was therefore used in binding experiments with purified PED. 
Preliminary ELISA assays confirmed the binding of PED to Trx-His6-D4 and the lack 
of any interference by the Trx tag. Further binding experiments, carried out with 
Biacore3000, allowed the determination of the kinetic parameters and an evaluation 
of the dissociation constant that was estimated to be 2±1x10-7 M-1. 
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Laura Tornatore, Simona M. Monti, Nina Dathan, Annamaria Sandomenico, 
Daniela Marasco, Nunzianna Doti, Francesca Viparelli, Maddalena Pizzulo, Mariano 
Amoroso, Ettore Benedetti, Carlo Pedone, Menotti Ruvo. Expression, purification and 
characterization of Gadd45β. 10th Naples Workshop on Bioactive Peptides, 2006. 
Introduction: The Gadd45 family of proteins is involved in a wealth of cellular 
events. They are key mediators of cell cycle arrest, apoptosis, signal transduction 
and cell survival, often stimulating opposite signals depending on cell types and/or 
status. Gadd45β, as an example, prevents apoptotic cell death in response to 
TNFalpha (De Smaele, Zazzeroni et al. 2001), whereas it can also favour apoptosis 
following TGFbeta stimulation (Lu, Ferrandino et al. 2004). Despite the increasing 
interest around this protein class, little is known about their structural organization. As 
it has been demonstrated that Gadd45α is able to self associate in small oligomers 
that can have a role in protein functionality (Kovalsky, Lung et al. 2001), we have 
investigated such aspects in human Gadd45β. To this aim, the protein has been 
prepared, purified and refolded and a preliminary structural characterization by CD 
has also been carried out. 
Result and Discussion: Initial expression and purification experiments were all 
performed with the original pET28aGADD45β clone. However, although the 
purification appeared to work well, when samples were electrophorated under 
nondenaturing conditions following gel filtration GADD45β appeared to run as a 
dimer, trimer or even higher form of oligomers. Although GADD45α reportedly exists 
predominantly as a dimer (Kovalsky et al, 2001), there exists no evidence as yet that 
GADD45β also exists as an oligomer. Initial crystallization experiments proved 
fruitless, so GADD45β was recloned in two alternative expression vectors with either 
a His6 or GST tag and there appeared no further problems of oligomerization. The 
recombinant construct pGEX6P-GADD45β, which allows expression of the protein as 
a GST-fusion product containing a highly specific cleavage site for PreScission 
Protease upstream of the GADD protein, was finally selected. The recombinant 
protein obtained after GST removal had the sequence reported in Fig. 1. The applied 
overexpression system was quite efficient, producing more than 6 mg of highly 
purified protein from 1L of induced culture under the reported conditions. The purity 
of the protein was estimated to be 98% by SDS-Page after Mono Q purification. The 
same purity level was estimated by analyzing the protein by LC-MS using a C18 or a 
C4 column and PDA or mass spectrometer to monitor the eluate. The protein was 
characterized by several techniques, including MW determination of the whole 
protein and also tryptic fragments obtained upon extensive digestion. The 
experimental MW was 18096.6±0.5 Da, in very good agreement with the theoretical 
value of 18098.3 Da, inclusive of the GPLGS fragment left by PreScission protease 
cleavage (Fig. 1, underlined) and assuming that all cysteines were in the reduced 
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state. Trypsin treatment gave rise to all the expected fragments, as identified by 
molecular weight determination upon LC-MS analysis, all without any inter- or 
intramolecular bridge. The lack of internally linked cysteines was also confirmed by 
analyzing the same sample after extensive reduction in 10 mM DTT and observing 
the same peaks pattern as in non reducing conditions. To further address the 
presence/absence of internal disulfides, we carried out an extensive alkylation 
reaction on the purified protein in the absence of any reducing agent, using 4-VP. 
The resulting product was again analyzed by LC-MS under the reported conditions, 
showing an increase of MW of 630.8 Da, corresponding to the incorporation of six 4-
VP moieties. Data concerning the capacity of GADD45 proteins to oligomerize 
(Kovalsky et al., 2001) are apparently in contrast with our results which, indeed, show 
that GADD45β could be present as a monomer. Gel filtration and native 
electrophoresis experiments have not yet addressed this point, as some oligomers 
can be held together by covalent linkages depending only on concentration 
conditions. The secondary structure of recombinant GADD45β was investigated by 
means of CD in the far-UV region. The spectrum of native GADD45β showed two 
negative bands at 209 and 219 nm and a positive band at 195 nm. This pattern 
suggested the presence of a folded structure in solution with a predominantly high α-
helical content. To further assess the achievement of the correct folding, we 
demonstrate that Gadd45β is able to bind in a dose-dependent fashion a peptide 
derived by MKK7, a kinase involved in the mechanism, mediated by Gadd itself, of 
suppression of apoptosis promoted by death receptors (Papa et al., 2004). 
 
Figure1: Aminoacidic sequence of recombinant Gadd45β; the added N-terminal 
pentapeptide GPLGS is in italics and underlined; cysteine residues are in bold and 
underlined. 
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